Optimal Designs for Multi-Arm Phase II/III Drug Development Programs

References

• Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., and Facon, T. (2014), “Lenalidomide and Dexamethasone in Transplant-Ineligible Patients With Myeloma,” New England Journal of Medicine, 371, 906–917. DOI: 10.1056/NEJMoa1402551.
   PubMed Web of Science ®Google Scholar
• Brückner, M., Titman, A., and Jaki, T. (2017), “Estimation in Multi-Arm Two-Stage Trials With Treatment Selection and Time-to-Event Endpoint,” Statistics in Medicine, 36, 3137–3153. DOI: 10.1002/sim.7367.
   PubMed Web of Science ®Google Scholar
• Dunnett, C. W. (1955), “A Multiple Comparison Procedure for Comparing Several Treatments With a Control,” Journal of the American Statistical Association, 50, 1096–1121. DOI: 10.1080/01621459.1955.10501294.
   Web of Science ®Google Scholar
• European Medicines Agency (2016), “Guideline on Multiplicity Issues in Clinical Trials,” Draft, Technical Report, EMEA.
   Google Scholar
• Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J. D., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., De La Rubia, J., White, D., Binder, D., Lu, J., Anderson, K. C., Moreau, P., Attal, M., Perrot, A., Arnulf, B., Qiu, L., Roussel, M., Boyle, E., Manier, S., Mohty, M., Avet-Loiseau, H., Leleu, X., Ervin-Haynes, A., Chen, G., Houck, V., Benboubker, L., and Hulin, C. (2018), “Final Analysis of Survival Outcomes in the Phase 3 FIRST Trial of Up-Front Treatment for Multiple Myeloma,” Blood, 131, 301–310. DOI: 10.1182/blood-2017-07-795047.
   PubMed Web of Science ®Google Scholar
• Freidlin, B., Korn, E. L., Gray, R., and Martin, A. (2008), “Multi-Arm Clinical Trials of New Agents: Some Design Considerations,” Clinical Cancer Research, 14, 4368–4371. DOI: 10.1158/1078-0432.CCR-08-0325.
   PubMed Web of Science ®Google Scholar
• Genz, A., Bretz, F., Xuefei Mi, T., Leisch, F., Scheipl, F., and Hothorn, T. (2019), “mvtnorm: Multivariate Normal and t Distributions,” R Package Version 1.0–7, available at http://CRAN.R-project.org/package=mvtnorm.
   Google Scholar
• Götte, H., Schüler, A., Kirchner, M., and Kieser, M. (2015), “Sample Size Planning for Phase II Trials Based on Success Probabilities for Phase III,” Pharmaceutical Statistics, 14, 515–524. DOI: 10.1002/pst.1717.
   PubMed Web of Science ®Google Scholar
• Horn, M., and Vollandt, R. (1998), “Sample Sizes for Comparisons of k Treatments With a Control Based on Different Definitions of the Power,” Biometrical Journal, 40, 589–612. DOI: 10.1002/(SICI)1521-4036(199809)40:5<589::AID-BIMJ589>3.0.CO;2-8.
   Web of Science ®Google Scholar
• IQWiG (2016), “Allgemeine Methoden,” Version 5.0, 10.07.2016, Technical Report.
   Google Scholar
• Jaki, T. (2015), “Multi-Arm Clinical Trials With Treatment Selection: What Can Be Gained and at What Price?,” Clinical Investigation, 5, 393–399. DOI: 10.4155/cli.15.13.
   Google Scholar
• James, N. D., and Sydes, M. R. (2017), “STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy. A Multi-Arm Multi-Stage Randomised Controlled Trial,” Trial Protocol Version 17.0, available at http://www.stampedetrial.org/centres/protocol-update-pack/.
   Google Scholar
• Jung, S. H., Kim, C., and Chow, S. C. (2008), “Sample Size Calculation for the Log-Rank Tests for Multi-Arm Trials With a Control,” Journal of the Korean Statistical Society, 37, 11–22. DOI: 10.1016/j.jkss.2007.11.001.
   Web of Science ®Google Scholar
• Kieser, M., Kirchner, M., Dölger, E., and Götte, H. (2018), “Optimal Planning of Phase II/III Programs for Clinical Trials With Multiple Endpoints,” Pharmaceutical Statistics, 17, 437–457.
   PubMed Web of Science ®Google Scholar
• Kirby, S., Burke, J., Chuang-Stein, C., and Sin, C. (2012), “Discounting Phase 2 Results When Planning Phase 3 Clinical Trials,” Pharmaceutical Statistics, 11, 373–385. DOI: 10.1002/pst.1521.
   PubMed Web of Science ®Google Scholar
• Kirchner, M., Kieser, M., Götte, H., and Schüler, A. (2016), “Utility-Based Optimization of Phase II/III Programs,” Statistics in Medicine, 35, 305–316. DOI: 10.1002/sim.6624.
   PubMed Web of Science ®Google Scholar
• Lachin, J. M. (2000), Biostatistical Methods: The Assessment of Relative Risks, New York: Wiley.
   Google Scholar
• Magirr, D., Jaki, T., and Whitehead, J. (2012), “A Generalized Dunnett Test for Multi-Arm Multi-Stage Clinical Studies With Treatment Selection,” Biometrika, 99, 494–501. DOI: 10.1093/biomet/ass002.
   Web of Science ®Google Scholar
• Microsoft Corporation and Weston, S. (2017), “doParallel: Foreach Parallel Adaptor for the ‘parallel’ Package,” R Package Version 1.0.11, available at https://CRAN.R-project.org/package=doParallel
   Google Scholar
• Narasimhan, B., Johnson, S., Hahn, T., Bouvier, A., and Kiêu, K. (2018), “cubature: Adaptive Multivariate Integration Over Hypercubes,” R Package Version 2.0.3, available at https://CRAN.R-project.org/package=cubature.
   Google Scholar
• O’Hagan, A., Stevens, J. W., and Campbell, M. J. (2005), “Assurance in Clinical Trial Design,” Pharmaceutical Statistics, 4, 187–201. DOI: 10.1002/pst.175.
   Web of Science ®Google Scholar
• Parmar, M. K. B., Barthel, F. M.-S., Sydes, M., Langley, R., Kaplan, R., Eisenhauer, E., Brady, M., James, N., Bookman, M. A., Swart, A.-M., Qian, W., and Royston, P. (2008), “Speeding up the Evaluation of New Agents in Cancer,” Journal of the National Cancer Institute, 100, 1204–1214. DOI: 10.1093/jnci/djn267.
   PubMedGoogle Scholar
• Parmar, M. K., Carpenter, J., and Sydes, M. R. (2014), “More Multiarm Randomised Trials of Superiority Are Needed,” The Lancet, 384, 283–284. DOI: 10.1016/S0140-6736(14)61122-3.
   PubMed Web of Science ®Google Scholar
• Patel, N. R., and Ankolekar, S. (2007), “A Bayesian Approach for Incorporating Economic Factors in Sample Size Design for Clinical Trials of Individual Drugs and Portfolios of Drugs,” Statistics in Medicine, 26, 4976–4988. DOI: 10.1002/sim.2955.
   PubMed Web of Science ®Google Scholar
• Patel, N. R., Ankolekar, S., Antonijevic, Z., and Rajicic, N. (2013), “A Mathematical Model for Maximizing the Value of Phase 3 Drug Development Portfolios Incorporating Budget Constraints and Risk,” Statistics in Medicine, 32, 1763–1777. DOI: 10.1002/sim.5731.
   PubMed Web of Science ®Google Scholar
• Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., and Schacht, A. L. (2010), “How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge,” Nature Reviews Drug Discovery, 9, 203.
   PubMed Web of Science ®Google Scholar
• Preussler, S. (2018), “Optimal Designs for Phase II/III Drug Development Programs Including Methods for Discounting of Phase II Results,” Technical Report.
   Google Scholar
• Preussler, S., Kieser, M., and Kirchner, M. (2019), “Optimal Sample Size Allocation and Go/No-Go Decision Rules for Phase II/III Programs Where Several Phase III Trials Are Performed,” Biometrical Journal, 61, 357–378. DOI: 10.1002/bimj.201700241.
   PubMed Web of Science ®Google Scholar
• R Core Team (2018), R: A Language and Environment for Statistical Computing, Vienna, Austria: R Foundation for Statistical Computing, available at https://www.R-project.org/.
   Google Scholar
• Roberts, Jr., T. G., Lynch, Jr., T. J., and Chabner, B. A. (2003), “The Phase III Trial in the Era of Targeted Therapy: Unraveling the ‘Go or No Go’ Decision,” Journal of Clinical Oncology, 21, 3683–3695. DOI: 10.1200/JCO.2003.01.204.
   PubMed Web of Science ®Google Scholar
• Royston, P., Parmar, M. K., and Qian, W. (2003), “Novel Designs for Multi-Arm Clinical Trials With Survival Outcomes With an Application in Ovarian Cancer,” Statistics in Medicine, 22, 2239–2256. DOI: 10.1002/sim.1430.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, D. (1981), “The Asymptotic Properties of Nonparametric Tests for Comparing Survival Distributions,” Biometrika, 68, 316–319. DOI: 10.1093/biomet/68.1.316.
   Web of Science ®Google Scholar
• Schoenfeld, D. (1983), “Sample-Size Formula for the Proportional-Hazards Regression Model,” Biometrics, 39, 499–503.
   PubMed Web of Science ®Google Scholar
• Stallard, N., and Todd, S. (2003), “Sequential Designs for Phase III Clinical Trials Incorporating Treatment Selection,” Statistics in Medicine, 22, 689–703. DOI: 10.1002/sim.1362.
   PubMed Web of Science ®Google Scholar
• Steensma, D. P., and Kantarjian, H. M. (2014), “Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care,” Journal of Clinical Oncology, 32, 376–378. DOI: 10.1200/JCO.2013.54.2548.
   PubMed Web of Science ®Google Scholar
• Sydes, M. R., Parmar, M. K., James, N. D., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Morgan, R. C., Sanders, K., and Royston, P. (2009), “Issues in Applying Multi-Arm Multi-Stage Methodology to a Clinical Trial in Prostate Cancer: the MRC STAMPEDE Trial,” Trials, 10, 39. DOI: 10.1186/1745-6215-10-39.
   PubMed Web of Science ®Google Scholar
• Wason, J., Magirr, D., Law, M., and Jaki, T. (2016), “Some Recommendations for Multi-Arm Multi-Stage Trials,” Statistical Methods in Medical Research, 25, 716–727. DOI: 10.1177/0962280212465498.
   PubMed Web of Science ®Google Scholar